tirzepatide vs dulaglutide โ๏ธ Cardiovascular Outcomes with versus in Type 2 Diabetes ๐ BACKGROUND Tirzepatide, a dual incretin agonist of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, has favorable effects on Management of type 2 diabetes
Description
Around 20% of participants taking tirzepatide experienced weight loss.
Tirzepatide injections require precise refrigeration to maintain effectiveness
Non-target lesion progression was found in 10.19% (11/108) patient of the GLP-1RA group and 22.12% (23/104) in the control group (P=0.037)
Miami, Coral Gables & Pinecrest FL Rafael Olartecoechea Offers Liraglutide for Medical Weight Loss
insurance), a limited evaluation of long-term costs associated with either treatment modality and their co-morbidities, and the reality of patient preference providing subjective value to either modality
